On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.
Interferon (IFN)- free direct antiviral agents (DAAs) with rapid HCV eradication might evoke immunological reconstitutions, and some early recurrences of HCC after IFN-free DAAs have been reported. This study aimed to investigate whether natural killer group 2, member D (NKG2D) predicts early emerge...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5472371?pdf=render |
| _version_ | 1817986982959120384 |
|---|---|
| author | Po-Sung Chu Nobuhiro Nakamoto Nobuhito Taniki Keisuke Ojiro Takeru Amiya Yuko Makita Hiroko Murata Akihiro Yamaguchi Shunsuke Shiba Rei Miyake Tadashi Katayama Aya Ugamura Akihiko Ikura Karin Takeda Hirotoshi Ebinuma Hidetsugu Saito Takanori Kanai |
| author_facet | Po-Sung Chu Nobuhiro Nakamoto Nobuhito Taniki Keisuke Ojiro Takeru Amiya Yuko Makita Hiroko Murata Akihiro Yamaguchi Shunsuke Shiba Rei Miyake Tadashi Katayama Aya Ugamura Akihiko Ikura Karin Takeda Hirotoshi Ebinuma Hidetsugu Saito Takanori Kanai |
| author_sort | Po-Sung Chu |
| collection | DOAJ |
| description | Interferon (IFN)- free direct antiviral agents (DAAs) with rapid HCV eradication might evoke immunological reconstitutions, and some early recurrences of HCC after IFN-free DAAs have been reported. This study aimed to investigate whether natural killer group 2, member D (NKG2D) predicts early emergence of HCC after IFN-free DAAs.We conducted a clinical practice-based observational study of 101 patients infected with genotype 1 HCV who received IFN-free (DAAs), and stratified them into those who did or did not develop early (i.e., during the 6-month surveillance period following treatment.) recurrence or occurrence of clinically evident HCC. We also analyzed the peripheral blood mononuclear cells, both before treatment and at end of treatment (EOT), of 24 of the patients who received IFN-free DAAs, and 16 who received IFN-combined protease inhibitor.We found early emergence of clinically evident HCC after IFN-free DAAs in 12 (12%) patients. Higher pre-treatment NKG2D expression, higher FIB-4 score, previous HCC history and failure to achieve sustained viral response were significant factors correlating to early HCC emergence. After IFN-free DAAs, a rapid decrease of NKG2D at EOT correlated with early HCC emergence in the IFN-free DAA-treated patients, but not in patients treated with the IFN-combined regimen. The decrease of NKG2D until EOT was predictive of early HCC emergence at a cut-off of -52% (AUC = 0.92).On-treatment decrease of NKG2D may be a useful predictor of early emerging HCC in patients treated with IFN-free DAAs. |
| first_indexed | 2024-04-14T00:16:11Z |
| format | Article |
| id | doaj.art-7eeb55e6b5724c96b32caa386a489078 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-14T00:16:11Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7eeb55e6b5724c96b32caa386a4890782022-12-22T02:23:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01126e017909610.1371/journal.pone.0179096On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.Po-Sung ChuNobuhiro NakamotoNobuhito TanikiKeisuke OjiroTakeru AmiyaYuko MakitaHiroko MurataAkihiro YamaguchiShunsuke ShibaRei MiyakeTadashi KatayamaAya UgamuraAkihiko IkuraKarin TakedaHirotoshi EbinumaHidetsugu SaitoTakanori KanaiInterferon (IFN)- free direct antiviral agents (DAAs) with rapid HCV eradication might evoke immunological reconstitutions, and some early recurrences of HCC after IFN-free DAAs have been reported. This study aimed to investigate whether natural killer group 2, member D (NKG2D) predicts early emergence of HCC after IFN-free DAAs.We conducted a clinical practice-based observational study of 101 patients infected with genotype 1 HCV who received IFN-free (DAAs), and stratified them into those who did or did not develop early (i.e., during the 6-month surveillance period following treatment.) recurrence or occurrence of clinically evident HCC. We also analyzed the peripheral blood mononuclear cells, both before treatment and at end of treatment (EOT), of 24 of the patients who received IFN-free DAAs, and 16 who received IFN-combined protease inhibitor.We found early emergence of clinically evident HCC after IFN-free DAAs in 12 (12%) patients. Higher pre-treatment NKG2D expression, higher FIB-4 score, previous HCC history and failure to achieve sustained viral response were significant factors correlating to early HCC emergence. After IFN-free DAAs, a rapid decrease of NKG2D at EOT correlated with early HCC emergence in the IFN-free DAA-treated patients, but not in patients treated with the IFN-combined regimen. The decrease of NKG2D until EOT was predictive of early HCC emergence at a cut-off of -52% (AUC = 0.92).On-treatment decrease of NKG2D may be a useful predictor of early emerging HCC in patients treated with IFN-free DAAs.http://europepmc.org/articles/PMC5472371?pdf=render |
| spellingShingle | Po-Sung Chu Nobuhiro Nakamoto Nobuhito Taniki Keisuke Ojiro Takeru Amiya Yuko Makita Hiroko Murata Akihiro Yamaguchi Shunsuke Shiba Rei Miyake Tadashi Katayama Aya Ugamura Akihiko Ikura Karin Takeda Hirotoshi Ebinuma Hidetsugu Saito Takanori Kanai On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. PLoS ONE |
| title | On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. |
| title_full | On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. |
| title_fullStr | On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. |
| title_full_unstemmed | On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. |
| title_short | On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C. |
| title_sort | on treatment decrease of nkg2d correlates to early emergence of clinically evident hepatocellular carcinoma after interferon free therapy for chronic hepatitis c |
| url | http://europepmc.org/articles/PMC5472371?pdf=render |
| work_keys_str_mv | AT posungchu ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT nobuhironakamoto ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT nobuhitotaniki ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT keisukeojiro ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT takeruamiya ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT yukomakita ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT hirokomurata ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT akihiroyamaguchi ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT shunsukeshiba ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT reimiyake ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT tadashikatayama ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT ayaugamura ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT akihikoikura ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT karintakeda ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT hirotoshiebinuma ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT hidetsugusaito ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc AT takanorikanai ontreatmentdecreaseofnkg2dcorrelatestoearlyemergenceofclinicallyevidenthepatocellularcarcinomaafterinterferonfreetherapyforchronichepatitisc |